Renova Therapeutics Selects Worldwide Clinical Trials

January 17, 2017

Renova Therapeutics has announced the selection of Worldwide Clinical Trials as its CRO for an upcoming gene therapy study.

Renova Therapeutics has announced the selection of Worldwide Clinical Trials as its CRO for an upcoming gene therapy study. Worldwide Clinical Trials will support the Phase III study of RT-100 AC6 gene transfer for the treatment of patients with reduced ejection fraction heart failure.

Read the full release here

Related Content:

News